Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia

Journal of Nephrology

Volumn 18, Issue 6, 2005, Pages 739-748

  Maduell, Francisco ^a   Gorriz, Jose L ^b   Pallardo, Luis M ^b   Pons, Ramon ^a   Santiago, Carlos ^c  

^a Castellon General Hospital   (Spain)

^b Hospital Peset   (Spain)

^c Alicante General Hospital   (Spain)

Author keywords

Bone disease; Cardiovascular risk; Hemodialysis; K DOQI guidelines; Mineral metabolism

Indexed keywords

ALFACALCIDOL; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; PHOSPHATE BINDING AGENT; PHOSPHOROUS ACID; SEVELAMER; VITAMIN D;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ARTICLE; BONE DISEASE; BONE METABOLISM; CALCIUM METABOLISM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MULTICENTER STUDY; PARATHYROID DISEASE; PARATHYROIDECTOMY; PRACTICE GUIDELINE; SPAIN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CALCIUM; CROSS-SECTIONAL STUDIES; DIALYSIS SOLUTIONS; FEMALE; HUMANS; HYPOCALCEMIA; INCIDENCE; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; VITAMIN D;

EID: 30644456522     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-17.
2. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-37.
3. Kessler M, Canaud B, Pedrini LA. The EBPG expert group on haemodialysis. European best practice guidelines for haemodialysis. Nephrol Dial Transplant 2002; 17 (suppl 7): S1-111.
4. National Kideney Foundation. K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (suppl 4): S1-201.
5. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2004; 44 (suppl 3): S34-8.
6. Yokoyama K, Katoh N, Kubo H, Murai S, Imamura N, Shoji R, Yamamoto H, Shigematsu T, Nakayama M, Takasu S, Kono T, Yoshida T, Hosoya T. Clinical significance of the K/DOQI bone guidelines in Japan. Am J Kidney Dis 2004; 44: 383-4.
7. Aly ZA, González EA, Martín KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: An uphill battle. Am J Nephrol 2004; 24: 422-6.
8. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerlick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
9. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
10. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-9.
11. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8.
12. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernández E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; 85: S111-4.
13. Avram MM, Mittman N, Wyint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-7.
14. Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002; 39: 1245-54.
15. Wing AJ. Optimum calcium concentration of dialysis fluid for maintenance haemodialysis. Br Med J 1968; 4: 145-9.
16. Argiles A, Mion CM, Thomas M. Calcium balance and intact PTH variations during hemodiafiltration. Nephrol Dial Transplant 1995; 10: 2083-9.
17. Fernández E, Borrás M, Pais B, Montoliu J. Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol 1995; 6: 132-5.
18. Chertow GM, Burke SK, Dillon MA, Slatoposky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-14.
19. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.
20. Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, Boitte F, Brazier M, Moriniere P, Fournier A. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomised study. Nephrol Dial Transplant 2003; 18: 582-9.
21. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernández E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002; 92: 499-500.
22. Moe SM, Coburn JW, Quarles LD, Goodman WG, Chertow GM, Block GA, Drüeke T, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achievement of proposed NKF-K/DOQI bone metabolism and disease targets: treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism. J Am Soc Nephrol 2003; 14: 48A.
23. de Francisco AL, Suranyi M, Cunningham J, Messa P, Locatelli F, Evenepoel P, Fournier A, González MT, Ureña P, Holzer H, Brink HS, Johnson D, Kramar R, Zani V, Hutton S, Turner SA, Drüeke T. Greater achievement of NKF-K/DOQI bone metabolism and disease targets with oral cinacalcet HCl in an European/Australian phase 3 study in hemodialysis patients. Abstract book XLI Congress EDTA 2004; 319.
24. Lorenzo V, Martín M, Rufino M, Jiménez A, Martin Malo A, Sánchez E, Hernández D, Rodríguez M, Torres A. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 2001; 37: 1260-6.
25. Malberti F, Marcelli D, Conte F, Limido A, Spoti D, Locatelli F. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001; 12: 1242-8.
26. European Best Practice Guidelines Expert Group on Haemodialysis, European Renal Association. Section VII. Vascular disease and risk factors. VII.3 Hyperphosphatemia and calcium-phosphorus ion product. Nephrol Dial Transplant 2002; 17 (suppl 7): S95-6.